



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 54
- (48) Corrigendum issued on:
02.11.2005 Bulletin 2005/44
- (45) Date of publication and mention
of the grant of the patent:
27.07.2005 Bulletin 2005/30
- (21) Application number: **02798231.3**
- (22) Date of filing: **13.09.2002**
- (51) Int Cl.7: **C07D 471/04, A61P 35/00**
- (86) International application number:
PCT/US2002/029154
- (87) International publication number:
WO 2003/022846 (20.03.2003 Gazette 2003/12)

(54) **1-GLYOXYLAMIDE INDOLIZINES FOR TREATING CANCER**

1-GLYOXYLAMIDINDOLIZINE ZUR BEHANDLUNG VON KREBS

INDOLIZINES DE 1-GLYOXYLAMIDE PERMETTANT DE TRAITER LE CANCER

- (84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
AL LT LV MK RO SI
- (30) Priority: **13.09.2001 US 322020 P**
- (43) Date of publication of application:
30.06.2004 Bulletin 2004/27
- (60) Divisional application:
05016203.1
- (73) Proprietor: **Synta Pharmaceuticals Corporation**
Lexington, MA 02421 (US)
- (72) Inventors:
• **KOYA, Keizo**
Chestnut Hill, MA 02467 (US)
- **SUN, Lijun**
Harvard, MA 01451 (US)
 - **ONO, Mitsunori**
Lexington, MA 02421 (US)
 - **YING, Weiwen**
Ayer, MA 01432 (US)
 - **LI, Hao**
Brookline, MA 02446 (US)
- (74) Representative:
Luderschmidt, Schüler & Partner GbR
Patentanwälte,
John-F.-Kennedy-Strasse 4
65189 Wiesbaden (DE)
- (56) References cited:
GB-A- 2 287 706 **US-B1- 6 214 855**

EP 1 432 709 B8

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).